Assessing infection risk with biologic agents in RA: methodological challenges
- 1 May 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Reviews Rheumatology
- Vol. 5 (5), 288-291
- https://doi.org/10.1038/nrrheum.2009.51
Abstract
Patients with rheumatoid arthritis (RA) are at increased risk of infection compared with the general population. As new DMARDs, in particular biologic agents, become more widely prescribed for the treatment of RA, adverse events that were not previously identified in randomized, controlled trials might develop, including opportunistic and serious infections. Understanding the strengths and weaknesses of data derived from randomized clinical trials, registries and meta-analyses is necessary to interpret the results of these studies. Whereas the risk of infection might be increased for the majority of biologic agents that have been approved for use in RA, differences between these agents might affect patients' susceptibility to specific types of infection, immunocompetence and relative risk of infection.Keywords
This publication has 24 references indexed in Scilit:
- American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritisArthritis Care & Research, 2008
- Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trialsAnnals Of The Rheumatic Diseases, 2008
- Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonistsAnnals Of The Rheumatic Diseases, 2007
- Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studiesArthritis & Rheumatism, 2007
- Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trialAnnals Of The Rheumatic Diseases, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF blockersAnnals Of The Rheumatic Diseases, 2006
- Safety of extended treatment with anakinra in patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2006
- Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritisRheumatology, 2005
- The safety of anakinra in high‐risk patients with active rheumatoid arthritis: Six‐month observations of patients with comorbid conditionsArthritis & Rheumatism, 2004